Skip to main content
Quest Diagnostics

Comparing ARR Versus Suppressed PRA as Screening Tests for Primary Aldosteronism

Comparing ARR Versus Suppressed PRA as Screening Tests for Primary Aldosteronism

Authors: Marcelli M, Bi C, Funder JW, McPhaul MJ

Citation: Hypertension. 2024 Jul 23. doi: 10.1161/HYPERTENSIONAHA.124.22884. Online ahead of print.

Specialties: Cardiology, Endocrinology, Cardiovascular disease

Download key summary

Rleated content

Conference Presentation
The diagnosis of primary aldosteronism: testing 2 screening approaches in a large reference laboratory population
Conference Presentation
Positivity Rates of Screening Criteria for Primary Aldosteronism: A Cohort Comparison Study
On-Demand Webinar
Early Identification of Type 2 Diabetes Risk for the Primary Care Setting
On-Demand Webinar
Cardiovascular Clinical Conversations: Inflammatory Markers for Defining Cardiovascular Risk
Test FAQ
CardioIQ® Insulin Resistance Panel with Score
On-Demand Webinar
Combating A Silent Killer: An Evidence-Based Update on the Treatment of Hypertension
On-Demand Webinar
The Continuum of Kidney Disease Care: From Identification to referral
Test FAQ
Apolipoprotein L1 (APOL1) Renal Risk Variant Genotyping

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.